[Skip to Content]
[Skip to Content Landing]
Article
May 15, 1987

A Mass Vaccination Program in Taiwan Against Hepatitis B Virus Infection in Infants of Hepatitis B Surface Antigen—Carrier Mothers

Author Affiliations

From the Science and Technology Advisory Group (Drs Chen, Sung, and Lo) and the Department of Health (Drs T.-C. Hsu, S.-T. Hsu, Kuo, and Shih and Ms N. H.-M. Hsu), The Executive Yuan, Taipei, Taiwan, Republic of China.

From the Science and Technology Advisory Group (Drs Chen, Sung, and Lo) and the Department of Health (Drs T.-C. Hsu, S.-T. Hsu, Kuo, and Shih and Ms N. H.-M. Hsu), The Executive Yuan, Taipei, Taiwan, Republic of China.

JAMA. 1987;257(19):2597-2603. doi:10.1001/jama.1987.03390190075023
Abstract

To combat hepatitis B virus (HBV) infection in Taiwan, a mass immunoprophylaxis program was launched on July 1,1984, aiming first at prevention of chronic HBV carriage from perinatal mother-to-infant infection. In the first 15-month period, 352 721 (78%) of 450 585 pregnant women were screened for hepatitis B surface antigen (HBsAg); HBsAg was present in 62 359 (18%), with 50% of them categorized as highly infectious. Infants born to HBsAg-positive women were given 5 μg of a plasma-derived hepatitis B vaccine at ages 1,5, and 9 weeks, with a booster at age 12 months. Infants of highly infectious carrier mothers received an additional 0.5 mL of hepatitis B immune globulin within 24 hours after birth. The coverage rate of the hepatitis B immune globulin was 77% in 27375 infants born to highly infectious mothers, and that of the first, second, third, and the fourth doses of vaccine was 88%, 86%, 84%, and 71%, respectively, in infants of 55620 carrier mothers. The reported untoward reactions to immunization were negligible. We conclude that a mass hepatitis B vaccination program is feasible in hyperendemic areas such as Taiwan; this should be a significant step toward the effective control of HBV infection in these areas.

(JAMA 1987;257:2597-2603)

×